Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000281593 corresponds to a "readthrough" transcript joining the **ZNRF2** gene (an E3 ubiquitin ligase regulating mTORC1 signaling and lysosomal function[1][2]) and **LINC01176** (a long non-coding RNA). Readthrough transcripts usually result from transcription extending from one gene into an adjacent gene and are often products of aberrant transcription or incomplete annotation, not established protein-coding or functional biological molecules. This entity is not recognized as a canonical protein or therapeutic target, does not have characterized molecular classification, biological function, or disease role, and has no established pharmacology or biomarker utility[3]. The relevant canonical proteins are ZNRF2 and, separately, LINC01176. **Note:** All functional and disease-related literature concerns ZNRF2, not the "ZNRF2-LINC01176 readthrough" product. For research on targets with therapeutic potential, refer to ZNRF2, not the readthrough transcript.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ZNRF2-LINC01176 readthrough.